![Thomas Gidoin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Gidoin
Director Financiero/CFO en
OSE IMMUNOTHERAPEUTICS
.
Perfil
Thomas Gidoin is Chief Financial Officer & Deputy CEO at OSE Immunotherapeutics SA since 2026.
Formerly, Controller at Ipsen SA from 2008 to 2011, Vice President-Finance at DBV Technologies SA from 2012 to 2015, and Chief Financial Officer at Gensight Biologics SA from 2015 to 2024.
Education includes graduate degrees from Ecole Supérieure de Gestion et Finances and NEOMA Business School.
Cargos activos de Thomas Gidoin
| Empresas | Cargo | Inicio |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Director Financiero/CFO | 20/08/2025 |
Antiguos cargos conocidos de Thomas Gidoin.
| Empresas | Cargo | Fin |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director Financiero/CFO | 26/01/2024 |
| DBV TECHNOLOGIES | Director Financiero/CFO | 01/01/2015 |
| IPSEN | Comptroller/Controller/Auditor | 01/01/2011 |
Formación de Thomas Gidoin.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
29
Relaciones de 1er grado
6
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Ecole Supérieure de Gestion et Finances
 Ecole Supérieure de Gestion et Finances Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
NEOMA Business School
 NEOMA Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Gidoin
